Aβ42-binding peptoids as amyloid aggregation inhibitors and detection ligands

ACS Chemical Neuroscience

Volumn 4, Issue 6, 2013, Pages 952-962

  Luo, Yuan ^a   Vali, Sheetal ^a   Sun, Suya ^a   Chen, Xuesong ^a   Liang, Xia ^a   Drozhzhina, Tatiana ^b   Popugaeva, Elena ^b   Bezprozvanny, Ilya ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b PETER THE GREAT ST PETERSBURG POLYTECHNIC UNIVERSITY   (Russian Federation)

Author keywords

Alzheimer's disease; beta amyloid peptide (42 40); hippocampal neurons; peptoids; scyllo inositol

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; INHIBITOR OF AMYLOID 1; INHIBITOR OF AMYLOID 2; PEPTOID; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); AMYLOID PROTEIN; LIGAND; PEPTIDE FRAGMENT; PROTEIN BINDING;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BINDING ASSAY; BLOOD BRAIN BARRIER; BRAIN NERVE CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; FLUORESCENCE; HIPPOCAMPUS; MEMBRANE PERMEABILITY; MOUSE; NEUROPROTECTION; NONHUMAN; PEPTIDE LIBRARY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DRUG EFFECTS; HUMAN; METABOLISM; NERVE CELL; PHYSIOLOGY; SYNTHESIS;

AMYLOID BETA-PEPTIDES; AMYLOIDOGENIC PROTEINS; ANIMALS; CELLS, CULTURED; HUMANS; LIGANDS; MICE; NEURONS; PEPTIDE FRAGMENTS; PEPTOIDS; PROTEIN BINDING;

EID: 84879772906     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn400011f     Document Type: Article

References (64)

1. Hardy, J. and Selkoe, D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297, 353-356
2. Karran, E., Mercken, M., and De Strooper, B. (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics Nat. Rev. Drug Discovery 10, 698-712
3. Amijee, H. and Scopes, D. I. (2009) The quest for small molecules as amyloid inhibiting therapies for Alzheimer's disease J. Alzheimer's Dis. 17, 33-47
4. DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J. C., Paul, S. M., and Holtzman, D. M. (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease Proc. Natl. Acad. Sci. U.S.A. 98, 8850-8855
5. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vandevert, C., Walker, S., Wogulis, M., Yednock, T., Games, D., and Seubert, P. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 400, 173-177
6. Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., and Orgogozo, J. M. (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial Neurology 64, 1553-1562
7. Banks, W. A. (2008) Developing drugs that can cross the blood-brain barrier: applications to Alzheimer's disease BMC Neurosci. 9 (Suppl 3) S2
8. Tanzi, R. E. and Bertram, L. (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective Cell 120, 545-555
9. McLaurin, J., Kierstead, M. E., Brown, M. E., Hawkes, C. A., Lambermon, M. H., Phinney, A. L., Darabie, A. A., Cousins, J. E., French, J. E., Lan, M. F., Chen, F., Wong, S. S., Mount, H. T., Fraser, P. E., Westaway, D., and St George-Hyslop, P. (2006) Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model Nat. Med. 12, 801-808
10. Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., Regan, C. M., Walsh, D. M., Sabatini, B. L., and Selkoe, D. J. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory Nat. Med. 14, 837-842
11. Walsh, D. M., Townsend, M., Podlisny, M. B., Shankar, G. M., Fadeeva, J. V., El Agnaf, O., Hartley, D. M., and Selkoe, D. J. (2005) Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation J. Neurosci. 25, 2455-2462
12. Wang, J., Ho, L., Zhao, W., Ono, K., Rosensweig, C., Chen, L., Humala, N., Teplow, D. B., and Pasinetti, G. M. (2008) Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease J. Neurosci. 28, 6388-6392
13. Wu, Y., Wu, Z., Butko, P., Christen, Y., Lambert, M. P., Klein, W. L., Link, C. D., and Luo, Y. (2006) Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans J. Neurosci. 26, 13102-13113
14. Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., and Cole, G. M. (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo J. Biol. Chem. 280, 5892-5901
15. Austen, B. M., Paleologou, K. E., Ali, S. A., Qureshi, M. M., Allsop, D., and El-Agnaf, O. M. (2008) Designing peptide inhibitors for oligomerization and toxicity of Alzheimer's beta-amyloid peptide Biochemistry 47, 1984-1992
16. Nerelius, C., Sandegren, A., Sargsyan, H., Raunak, R., Leijonmarck, H., Chatterjee, U., Fisahn, A., Imarisio, S., Lomas, D. A., Crowther, D. C., Stromberg, R., and Johansson, J. (2009) Alpha-helix targeting reduces amyloid-beta peptide toxicity Proc. Natl. Acad. Sci. U.S.A. 106, 9191-9196
17. Park, S. Y. and Kim, D. S. (2002) Discovery of natural products from Curcuma longa that protect cells from beta-amyloid insult: a drug discovery effort against Alzheimer's disease J. Nat. Prod. 65, 1227-1231
18. Takahashi, T. and Mihara, H. (2008) Peptide and protein mimetics inhibiting amyloid beta-peptide aggregation Acc. Chem. Res. 41, 1309-1318
19. Gervais, F., Paquette, J., Morissette, C., Krzywkowski, P., Yu, M., Azzi, M., Lacombe, D., Kong, X., Aman, A., Laurin, J., Szarek, W. A., and Tremblay, P. (2007) Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis Neurobiol. Aging. 28, 537-547
20. Chen, X., Wu, J., Luo, Y., Liang, X., Supnet, C., Kim, M. W., Lotz, G. P., Yang, G., Muchowski, P. J., Kodadek, T., and Bezprozvanny, I. (2011) Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of huntington's disease Chem. Biol. 18, 1113-1125
21. Miller, S. M., Simon, R. J., Ng, S., Zuckermann, R. N., Kerr, J. M., and Moos, W. H. (1994) Proteolytic studies of homologous peptide and N-substituted glycine peptoid oligomers Bioorg. Med. Chem. Lett. 4, 2657-2662
22. Cho, S., Choi, J., Kim, A., Lee, Y., and Kwon, Y. U. (2010) Efficient solid-phase synthesis of a series of cyclic and linear peptoid-dexamethasone conjugates for the cell permeability studies J. Comb. Chem. 12, 321-326
23. Miller, S. M., Simon, R. J., Ng, S., Zuckermann, R. N., Kerr, J. M., and Moos, W. H. (1995) Comparison of the proteolytic susceptibilities of homologous l -amino-acid, d -amino-acid, and N-substituted glycine peptide and peptoid oligomers Drug Dev. Res. 35, 20-32
24. Zuckermann, R. N. and Kodadek, T. (2009) Peptoids as potential therapeutics Curr. Opin. Mol. Ther. 11, 299-307
25. Lim, H. S., Reddy, M. M., Xiao, X., Wilson, J., Wilson, R., Connell, S., and Kodadek, T. (2009) Rapid identification of improved protein ligands using peptoid microarrays Bioorg. Med. Chem. Lett. 19, 3866-3869
26. Simon, R. J., Kania, R. S., Zuckermann, R. N., Huebner, V. D., Jewell, D. A., Banville, S., Ng, S., Wang, L., Rosenberg, S., Marlowe, C. K., Spellmeyer, D. C., Tans, R., Frankelo, A. D., Santi, D. V., Cohen, F. E., and Bartletts, P. A. (1992) Peptoids: a modular approach to drug discovery Proc. Natl. Acad. Sci. U.S.A. 89, 9367-9371
27. Kodadek, T. and Bachhawat-Sikder, K. (2006) Optimized protocols for the isolation of specific protein-binding peptides or peptoids from combinatorial libraries displayed on beads Mol. BioSyst. 2, 25-35
28. Zuckermann, R. N., Martin, E. J., Spellmeyer, D. C., Stauber, G. B., Shoemaker, K. R., Kerr, J. M., Figliozzi, G. M., Goff, D. A., Siani, M. A., and Simon, R. J. 1994, Discovery of nanomolar ligands for 7-transmembrane G-protein-coupled receptors from a diverse N-(substituted)glycine peptoid library J. Med. Chem. 37, 2678-2685
29. Hara, T., Durell, S. R., Myers, M. C., and Appella, D. H. (2006) Probing the structural requirements of peptoids that inhibit HDM2-p53 interactions J. Am. Chem. Soc. 128, 1995-2004
30. Alluri, P. G., Reddy, M. M., Bachhawat-Sikder, K., Olivos, H. J., and Kodadek, T. (2003) Isolation of protein ligands from large peptoid libraries J. Am. Chem. Soc. 125, 13995-14004
31. Bremner, J. B., Keller, P. A., Pyne, S. G., Boyle, T. P., Brkic, Z., David, D. M., Garas, A., Morgan, J., Robertson, M., Somphol, K., Miller, M. H., Howe, A. S., Ambrose, P., Bhavnani, S., Fritsche, T. R., Biedenbach, D. J., Jones, R. N., Buckheit, R. W., Watson, K. M., Baylis, D., Coates, J. A., Deadman, J., Jeevarajah, D., McCracken, A., and Rhodes, D. I. (2010) Binaphthyl-based dicationic peptoids with therapeutic potential Angew. Chem., Int. Ed. 49, 537-540
32. Brown, N. J., Dohm, M. T., de la Serna, J. B., and Barron, A. E. (2011) Biomimetic N-terminal alkylation of peptoid analogues of surfactant protein C Biophys. J. 101, 1076-1085
33. Roland, C. L., Lynn, K. D., Toombs, J. E., Dineen, S. P., Udugamasooriya, D. G., and Brekken, R. A. (2009) Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer PloS One 4, e7669
34. Lynn, K. D., Udugamasooriya, D. G., Roland, C. L., Castrillon, D. H., Kodadek, T. J., and Brekken, R. A. (2010) GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer BMC Cancer 10, 397
35. Udugamasooriya, D. G., Dineen, S. P., Brekken, R. A., and Kodadek, T. (2008) A peptoid antibody surrogate that antagonizes VEGF receptor 2 activity J. Am. Chem. Soc. 130, 5744-5752
36. Lim, H. S., Archer, C. T., and Kodadek, T. (2007) Identification of a peptoid inhibitor of the proteasome 19S regulatory particle J. Am. Chem. Soc. 129, 7750-7751
37. Reddy, M. M., Wilson, R., Wilson, J., Connell, S., Gocke, A., Hynan, L., German, D., and Kodadek, T. (2011) Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening Cell 144, 132-142
38. Zuckermann, R. N., Kerr, J. M., Kent, S. B. H., and Moos, W. H. (1992) Efficient Method for the Preparation of peptoids [Oligo(N-substituted glycines)] by submonomer solid-phase synthesis J. Am. Chem. Soc. 114, 10646-10647
39. Figliozzi, G. M., Goldsmith, R., Ng, S. C., Banville, S. C., and Zuckermann, R. N. (1996) Synthesis of N-substituted glycine peptoid libraries Methods Enzymol. 267, 437-447
40. Andrews, P. R. and Lloyd, E. J. (1982) Molecular conformation and biological activity of central nervous system active drugs Med. Res. Rev. 2, 355-393
41. Andrews, P. R. and Lloyd, E. J. (1983) A common structural basis for c.n.s. drug action J. Pharm. Pharm. 35, 516-518
42. Udugamasooriya, D. G., Ritchie, C., Brekken, R. A., and Kodadek, T. (2008) A peptoid antagonist of VEGF receptor 2 recognizes a 'hotspot' in the extracellular domain distinct from the hormone-binding site Bioorg. Med. Chem. 16, 6338-6343
43. LeVine, H., III. (2006) Biotin-avidin interaction-based screening assay for Alzheimer's beta-peptide oligomer inhibitors Anal. Biochem. 356, 265-272
44. Shen, L., Ji, H. F., and Zhang, H. Y. (2008) Why Is the C-terminus of Abeta(1-42) more unfolded than that of Abeta(1-40)? Clues from hydrophobic interaction J. Phy. Chem. B 112, 3164-3167
45. Yan, Y., Liu, J., McCallum, S. A., Yang, D., and Wang, C. (2007) Methyl dynamics of the amyloid-beta peptides Abeta40 and Abeta42 Biochem. Biophys. Res. Commun. 362, 410-414
46. Yam, A. Y., Wang, X., Gao, C. M., Connolly, M. D., Zuckermann, R. N., Bleu, T., Hall, J., Fedynyshyn, J. P., Allauzen, S., Peretz, D., and Salisbury, C. M. (2011) A universal method for detection of amyloidogenic misfolded proteins Biochemistry 50, 4322-4329
47. Baine, M., Georgie, D. S., Shiferraw, E. Z., Nguyen, T. P., Nogaj, L. A., and Moffet, D. A. (2009) Inhibition of Abeta42 aggregation using peptides selected from combinatorial libraries J. Pept. Sci. 15, 499-503
48. Kuperstein, I., Broersen, K., Benilova, I., Rozenski, J., Jonckheere, W., Debulpaep, M., Vandersteen, A., Segers-Nolten, I., Van Der Werf, K., Subramaniam, V., Braeken, D., Callewaert, G., Bartic, C., D'Hooge, R., Martins, I. C., Rousseau, F., Schymkowitz, J., and De Strooper, B. (2010) Neurotoxicity of Alzheimer's disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio EMBO J. 29, 3408-3420
49. Bolder, S. G., Sagis, L. M., Venema, P., and van der Linden, E. (2007) Thioflavin T and birefringence assays to determine the conversion of proteins into fibrils Langmuir 23, 4144-4147
50. Canovi, M., Markoutsa, E., Lazar, A. N., Pampalakis, G., Clemente, C., Re, F., Sesana, S., Masserini, M., Salmona, M., Duyckaerts, C., Flores, O., Gobbi, M., and Antimisiaris, S. G. (2011) The binding affinity of anti-Abeta1-42 MAb-decorated nanoliposomes to Abeta1-42 peptides in vitro and to amyloid deposits in post-mortem tissue Biomaterials 32, 5489-5497
51. McLaurin, J., Golomb, R., Jurewicz, A., Antel, J. P., and Fraser, P. E. (2000) Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity J. Biol. Chem. 275, 18495-18502
52. Townsend, M., Cleary, J. P., Mehta, T., Hofmeister, J., Lesne, S., O'Hare, E., Walsh, D. M., and Selkoe, D. J. (2006) Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers Ann. Neurol. 60, 668-676
53. Ma, K., Thomason, L. A., and McLaurin, J. (2012) scyllo-Inositol, preclinical, and clinical data for Alzheimer's disease Adv. Pharmacol. 64, 177-212
54. Sinha, S., Du, Z., Maiti, P., Klarner, F. G., Schrader, T., Wang, C., and Bitan, G. (2012) Comparison of three amyloid assembly inhibitors: The sugar scyllo-inositol, the polyphenol epigallocatechin gallate, and the molecular tweezer CLR01 ACS Chem. Neurosci. 3, 451-458
55. Kiessling, L. L., Gestwicki, J. E., and Strong, L. E. (2006) Synthetic multivalent ligands as probes of signal transduction Angew. Chem., Int. Ed. 45, 2348-2368
56. Reinke, A. A., Ung, P. M., Quintero, J. J., Carlson, H. A., and Gestwicki, J. E. (2010) Chemical probes that selectively recognize the earliest Aβ oligomers in complex mixtures J. Am. Chem. Soc. 132, 17655-17657
57. Gao, C. M., Yam, A. Y., Wang, X., Magdangal, E., Salisbury, C., Peretz, D., Zuckermann, R. N., Connolly, M. D., Hansson, O., Minthon, L., Zetterberg, H., Blennow, K., Fedynyshyn, J. P., and Allauzen, S. (2010) Abeta40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease PloS One 5, e15725
58. Braak, H. and Braak, E. (1991) Neuropathological stageing of Alzheimer-related changes Acta Neuropathol. 82, 239-259
59. Wu, H. Y., Hudry, E., Hashimoto, T., Kuchibhotla, K., Rozkalne, A., Fan, Z., Spires-Jones, T., Xie, H., Arbel-Ornath, M., Grosskreutz, C. L., Bacskai, B. J., and Hyman, B. T. (2010) Amyloid {beta} induces the morphological neurodegenerativetriad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation J. Neurosci. 30, 2636-2649
60. Broersen, K., Jonckheere, W., Rozenski, J., Vandersteen, A., Pauwels, K., Pastore, A., Rousseau, F., and Schymkowitz, J. (2011) A standardized and biocompatible preparation of aggregate-free amyloid beta peptide for biophysical and biological studies of Alzheimer's disease Protein Eng., Des. Sel. 24, 743-750
61. Tang, T. S., Slow, E., Lupu, V., Stavrovskaya, I. G., Sugimori, M., Llinas, R., Kristal, B. S., Hayden, M. R., and Bezprozvanny, I. (2005) Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease Proc. Natl. Acad. Sci. U.S.A. 102, 2602-2607
62. Zhang, H., Fu, Y., Altier, C., Platzer, J., Surmeier, D. J., and Bezprozvanny, I. (2006) CaV1.2 and CaV1.3 neuronal L-type calcium channels: differential targeting and signaling to pCREB Eur. J. Neurosci. 23, 2297-2310
63. Tang, T. S., Guo, C., Wang, H., Chen, X., and Bezprozvanny, I. (2009) Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model J. Neurosci. 29, 1257-1266
64. Liu, J., Tang, T. S., Tu, H., Nelson, O., Herndon, E., Huynh, D. P., Pulst, S. M., and Bezprozvanny, I. (2009) Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2 J. Neurosci. 29, 9148-9162